STOCKHOLM, March 25, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation [1] of potential future sales for Leqembi ...

A study of Roche's anti-amyloid drug gantenerumab has suggested that early treatment to remove amyloid plaques from the brain ...

Leqembi is an infusion therapy that targets and removes the beta-amyloid plaque that builds up in the brains of Alzheimer's ...

The drug, gantenerumab, was abandoned by its developers, but subsequent anti-amyloid drugs lecanemab ( Leqembi) and donanemab ...

Investigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing Alzheimer's symptoms by 50%.

While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...

More than 50% of those on continuous Leqembi treatment continued to show ... according to Christopher van Dyck of Yale University School of Medicine, who reported the results at AAIC.

Sera Prognostics Inc., The Pregnancy Company® , focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that ...

In a major Phase 3 clinical trial, lecanemab showed it could slow the decline in memory and thinking ability by 27% overall ...

allowing the entry of a new type of medicine in a market dominated by Pfizer's blockbuster Vyndaqel. Healthcare & Pharmaceuticalscategory· March 17, 2025 Incyte's skin disease drug fails to ...